DE602005010698D1 - Pyrrolopyridinderivate - Google Patents

Pyrrolopyridinderivate

Info

Publication number
DE602005010698D1
DE602005010698D1 DE602005010698T DE602005010698T DE602005010698D1 DE 602005010698 D1 DE602005010698 D1 DE 602005010698D1 DE 602005010698 T DE602005010698 T DE 602005010698T DE 602005010698 T DE602005010698 T DE 602005010698T DE 602005010698 D1 DE602005010698 D1 DE 602005010698D1
Authority
DE
Germany
Prior art keywords
pyrrolopyridinderivate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005010698T
Other languages
German (de)
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Giblin
Matthew Russell Johnson
William Leonard Mitchell
Alcide Perboni
Brian Peter Slingsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602005010698D1 publication Critical patent/DE602005010698D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005010698T 2004-06-09 2005-06-07 Pyrrolopyridinderivate Expired - Lifetime DE602005010698D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds
PCT/EP2005/006182 WO2005121140A1 (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Publications (1)

Publication Number Publication Date
DE602005010698D1 true DE602005010698D1 (de) 2008-12-11

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010698T Expired - Lifetime DE602005010698D1 (de) 2004-06-09 2005-06-07 Pyrrolopyridinderivate

Country Status (25)

Country Link
US (1) US7589206B2 (enExample)
EP (1) EP1753764B1 (enExample)
JP (1) JP2008501758A (enExample)
KR (1) KR20070034049A (enExample)
AR (1) AR050158A1 (enExample)
AT (1) ATE412651T1 (enExample)
AU (1) AU2005251913A1 (enExample)
BR (1) BRPI0511874A (enExample)
CA (1) CA2569887A1 (enExample)
DE (1) DE602005010698D1 (enExample)
DK (1) DK1753764T3 (enExample)
ES (1) ES2317244T3 (enExample)
HR (1) HRP20090034T3 (enExample)
IL (1) IL179603A0 (enExample)
MA (1) MA28686B1 (enExample)
MX (1) MXPA06014471A (enExample)
NO (1) NO20070067L (enExample)
PE (1) PE20060430A1 (enExample)
PL (1) PL1753764T3 (enExample)
PT (1) PT1753764E (enExample)
RU (1) RU2006147278A (enExample)
SI (1) SI1753764T1 (enExample)
TW (1) TW200611695A (enExample)
UY (1) UY28945A1 (enExample)
WO (1) WO2005121140A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
KR20220084426A (ko) * 2004-07-28 2022-06-21 다케다 야쿠힌 고교 가부시키가이샤 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
AR055601A1 (es) * 2005-08-09 2007-08-29 Glaxo Group Ltd Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides
US20090275611A1 (en) * 2006-04-07 2009-11-05 Boehringer Ingelheim International Gmbh Compounds Which Modulate The CB2 Receptor
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2011143740A (ru) 2009-03-30 2013-05-10 Астеллас Фарма Инк. Соединение пиримидина
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
HRP20161111T1 (hr) 2010-07-29 2016-11-18 Astellas Pharma Inc. Kondenzirani spojevi piridina kao ligandi cb2 kanabinoidnog receptora
WO2013140342A1 (en) * 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
HUE040645T2 (hu) 2013-06-26 2019-03-28 Abbvie Inc BTK-inhibitor primer karboxamidok
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
CN113271938A (zh) * 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3379404D1 (en) * 1982-12-29 1989-04-20 Kureha Chemical Ind Co Ltd Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
FI922347L (fi) 1990-01-05 1992-05-22 Pfizer Azaoxindolderivat.
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
JPH09509179A (ja) 1994-02-18 1997-09-16 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ２−ヘテロアリール−５，１１−ジヒドロ−６Ｈ−ジピリド［３，２−ｂ：２’，３’−ｅ］［１，４］ジアゼピン類及びＨＩＶ感染の予防又は処置におけるそれらの使用
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
ATE237023T1 (de) 1998-01-23 2003-04-15 Voith Paper Patent Gmbh Verfahren zur entfernung von feinen verunreinigungen aus einer faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6525072B1 (en) 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
WO2000053181A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2002538205A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
CA2367116A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3868500A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1171125A1 (en) 1999-03-10 2002-01-16 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
BR9916746A (pt) 1999-06-03 2005-01-11 Abbott Lab Compostos anti-inflamatórios que inibem adesão de célula
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
GEP20063751B (en) 2000-04-28 2006-02-27 Baxter Healthcare Sa 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
BR0110420A (pt) 2000-04-28 2003-07-01 Acadia Pharm Inc Agonistas muscarìnicos
DE60119124T2 (de) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP1315741A2 (en) 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies
AU2001288731B8 (en) 2000-09-06 2006-04-13 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
EP1324985A4 (en) 2000-10-02 2004-10-06 Merck & Co Inc PRENYL PROTEIN TRANSFERASE INHIBITORS
IL156776A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
WO2002062423A1 (en) 2001-02-02 2002-08-15 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
DE60217669D1 (de) 2001-05-14 2007-03-08 Bristol Myers Squibb Co Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
DE60216952T2 (de) 2001-10-19 2007-07-05 Transtech Pharma Inc. Beta-carbolin-derivate als ptp-inhibitoren
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
AU2003226724A1 (en) 2002-03-27 2003-10-08 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
ES2273077T3 (es) 2002-08-21 2007-05-01 Glaxo Group Limited Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2.
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
JP2006517966A (ja) 2003-02-14 2006-08-03 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate

Also Published As

Publication number Publication date
WO2005121140A1 (en) 2005-12-22
NO20070067L (no) 2007-02-09
TW200611695A (en) 2006-04-16
MXPA06014471A (es) 2007-03-21
JP2008501758A (ja) 2008-01-24
UY28945A1 (es) 2006-01-31
PE20060430A1 (es) 2006-05-25
US20070219229A1 (en) 2007-09-20
ATE412651T1 (de) 2008-11-15
MA28686B1 (fr) 2007-06-01
ES2317244T3 (es) 2009-04-16
KR20070034049A (ko) 2007-03-27
EP1753764A1 (en) 2007-02-21
PL1753764T3 (pl) 2009-04-30
CA2569887A1 (en) 2005-12-22
HRP20090034T3 (en) 2009-03-31
IL179603A0 (en) 2007-05-15
RU2006147278A (ru) 2008-07-20
EP1753764B1 (en) 2008-10-29
AR050158A1 (es) 2006-10-04
HK1104175A1 (en) 2008-01-04
US7589206B2 (en) 2009-09-15
DK1753764T3 (da) 2009-02-16
BRPI0511874A (pt) 2008-01-15
SI1753764T1 (sl) 2009-02-28
PT1753764E (pt) 2009-01-28
AU2005251913A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
NO2025046I1 (no) crizotinib - Forlenget
CY2019034I1 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE502005005116D1 (de) Wischblatt
DE502005005035D1 (de) Wischblatt
DE502005005628D1 (de) Wischblatt
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE602005010698D1 (de) Pyrrolopyridinderivate
DE502005006395D1 (de) Verschlusskappe
DE502005005991D1 (de) Sensorleuchte
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502005007739D1 (de) Kranballastierungssystem
DE502004012213D1 (de) Flachdichtung
DE202004017327U1 (de) Fitnessrad
DE502005007584D1 (de) Raftfahrzeuge
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005007637D1 (de) Flachdichtung
AT500198B1 (de) Ladewagen
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005007997D1 (de) Aftfahrzeug
ATE389633T1 (de) Omega-phenyloctanamide
DE502005005805D1 (de) Remsanlage
DE502005007686D1 (de) Gutverteileinrichtung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition